CellCentric raised $220 million in a Series D financing to advance its multiple myeloma program through registration and toward potential commercialization. The transatlantic biotech said the cash infusion supports an ongoing Phase 2 study and planned Phase 3 trial activity for its oral medicine targeting persistent disease.